Related references
Note: Only part of the references are listed.Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest
Farida Dakterzada et al.
FRONTIERS IN AGING NEUROSCIENCE (2021)
Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort
Silvia Ingala et al.
ALZHEIMERS & DEMENTIA (2021)
Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial
Anna Rosenberg et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment
Timothy S. Anderson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Taking the A Train? Limited Consistency of Aβ42 and the Aβ42/40 Ratio in the AT(N) Classification
Dominique Gouilly et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Bruno Dubois et al.
LANCET NEUROLOGY (2021)
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Harald Hampel et al.
NATURE REVIEWS NEUROLOGY (2021)
Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders
C. Eckerstrom et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2021)
Brain Atrophy Subtypes and the ATN Classification Scheme in Alzheimer's Disease
Nira Cedres et al.
NEURODEGENERATIVE DISEASES (2021)
The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up
Goril Rolfseng Grontvedt et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia
Meng-Shan Tan et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
The implications of different approaches to define AT(N) in Alzheimer disease
Niklas Mattsson-Carlgren et al.
NEUROLOGY (2020)
ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
Jarith L. Ebenau et al.
NEUROLOGY (2020)
Automatically computed rating scales from MRI for patients with cognitive disorders
Juha R. Koikkalainen et al.
EUROPEAN RADIOLOGY (2019)
ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Anja Soldan et al.
NEUROLOGY (2019)
Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
Clifford R. Jack et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Applying the ATN scheme in a memory clinic population The ABIDE project
Daniele Altomare et al.
NEUROLOGY (2019)
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease
Maria Joao Leitao et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Prevalence of preclinical Alzheimer disease Comparison of current classification systems
Silke Kern et al.
NEUROLOGY (2018)
The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment
Urban Ekman et al.
SCIENTIFIC REPORTS (2018)
Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment
Ines Baldeiras et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results
Betty M. Tijms et al.
CLINICAL CHEMISTRY (2018)
Atrial fibrillation and use of antithrombotic medications in older people: A population-based study
Mozhu Ding et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study
Clifford R. Jack et al.
LANCET NEUROLOGY (2017)
Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population
Daniela Bertens et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis
Hanneke F. M. Rhodius-Meester et al.
FRONTIERS IN AGING NEUROSCIENCE (2017)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Differential diagnosis of neurodegenerative diseases using structural MRI data
Juha Koikkalainen et al.
NEUROIMAGE-CLINICAL (2016)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
Julien Dumurgier et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Visual assessment of posterior atrophy development of a MRI rating scale
Esther L. G. E. Koedam et al.
EUROPEAN RADIOLOGY (2011)
The montreal cognitive assessment, MoCA:: A brief screening tool for mild cognitive impairment
ZS Nasreddine et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2005)
Share Paper
